Despite the preclinical and translational evidence for tumor immune modification with BRAF/MEK inhibitors and a PFS of 15.1-16.2 months in the 3 largest reported triplet-therapy trials, the toxicity incurred with triplet therapies has been challenging from a practical standpoint (13–15). This evidence concerns the gene BRAF and neoplasm.